WAYNE, Pa., July 10 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) today announced, for the third year in a row, its inclusion
in FORTUNE Small Business' top 100 fastest-growing small public companies
in America. FORTUNE Small Business, in conjunction with Zacks Investment
Research, evaluated publicly-traded companies with revenues of less than
$200 million and a stock price of more than $1, and companies were chosen
for their percentage growth in earnings, revenue, and stock performance
over the past three years. Escalon was ranked 82nd overall in 2006.
    Escalon Medical Corp.'s CEO, Richard J. DePiano commented, "We are
pleased to be ranked in this well-regarded list for three consecutive
years. This recognition reflects the efforts of a well-focused team and our
continued commitment to being a leading resource to our customers." In
addition to this recognition by FSB, Escalon was recognized by Forbes
Magazine as one of its "200 Best Small Companies" in November 2004.
    The FSB 100 list appears in the July/August issue of FORTUNE Small
Business and is available at FSB.com.
    Founded in 1987, Escalon develops markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices. Drew, which operates as a separate business unit, provides
instrumentation and consumables for the diagnosis and monitoring of medical
disorders in the areas of diabetes, cardiovascular diseases and hematology,
as well as veterinary hematology and blood chemistry. Escalon seeks to
utilize strategic partnerships to help finance its development programs and
is also seeking acquisitions to further diversify its product line to
achieve critical mass in sales and take better advantage of the Escalon's
distribution capabilities. Escalon has headquarters in Wayne, Pennsylvania
and manufacturing operations in Long Island, New York, New Berlin,
Wisconsin, Dallas, Texas, Oxford, Connecticut and Barrow-in-Furness, U.K.
    Note: This press release contains statements that are considered
forward- looking under the Private Securities Litigation Reform Act of
1995, including statements about Escalon's future prospects. They are based
on the Escalon's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially. The
uncertainties and risks include whether Escalon is able to implement its
growth and marketing strategies, improve upon the operations of Escalon's
business units, including the integration of Drew's operations and any
acquisitions it may undertake, if any, of which there can be no assurance,
generate cash and identify, finance and enter into business relationships
and acquisitions, uncertainties and risks related to new product
development, commercialization, manufacturing and market acceptance of new
products, marketing acceptance of existing products in new markets, the
continuity of royalty revenue, litigation and non- recurring expenses,
research and development activities, including failure to demonstrate
clinical efficacy, delays by regulatory authorities, scientific and
technical advances by Escalon or third parties, introduction of competitive
products, third party reimbursement and physician training as well as
general economic conditions. Further information about these and other
relevant risks and uncertainties may be found in Escalon's report on Form
10- K, and its other filings with the Securities and Exchange Commission,
all of which are available from the Commission as well as other sources.

Link to this page: